Oligonucleotide Therapy-based Drug Market, Global Outlook and Forecast 2023-2029
Report ID
42791
Publisher
Market Monitor Global
Published Date
07-Dec
Delivery Format
PDF
No of Report Page
146
Editor's Rating
US $3,250.00
US $4,225.00
US $4,875.00
  • Report Details 
    This research report provides a comprehensive analysis of the Oligonucleotide Therapy-based Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Oligonucleotide Therapy-based Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Oligonucleotide Therapy-based Drug, challenges faced by the industry, and potential opportunities for market players.
The global Oligonucleotide Therapy-based Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Oligonucleotide Therapy-based Drug market presents opportunities for various stakeholders, including Neuromuscular Diseases, hATTR. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Oligonucleotide Therapy-based Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Oligonucleotide Therapy-based Drug market was valued at US$ 60320 million in 2022 and is projected to reach US$ 14820 million by 2029, at a CAGR of 3.9% during the forecast period.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
Key Features:
The research report on the Oligonucleotide Therapy-based Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Oligonucleotide Therapy-based Drug market.
Market Overview: The report provides a comprehensive overview of the Oligonucleotide Therapy-based Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Antisense Oligonucleotides (ASO), siRNA), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Oligonucleotide Therapy-based Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Oligonucleotide Therapy-based Drug market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Oligonucleotide Therapy-based Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. 
Market Segmentation and Forecast: The report segment the Oligonucleotide Therapy-based Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Oligonucleotide Therapy-based Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Oligonucleotide Therapy-based Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Oligonucleotide Therapy-based Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Oligonucleotide Therapy-based Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Oligonucleotide Therapy-based Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
    Antisense Oligonucleotides (ASO)
    siRNA
    mRNA
Market segment by Application
    Neuromuscular Diseases
    hATTR
    COVID-19
    Other
Global Oligonucleotide Therapy-based Drug Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Major players covered
    Sarepta Therapeutics
    Ionis Pharmaceuticals
    Alnylam
    Biogen
    Nippon Shinyaku
    Sobi
    Novartis
    BioNTech
    Pfizer
    Moderna Therapeutics
    Jazz Pharmaceuticals
    CureVac
    Regulus Therapeutics
    ProQR
    Secarna
    MiNA Therapeutics
    Sylentis
    Arrowhead
    Silence Therapeutics
    Dicerna
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oligonucleotide Therapy-based Drug, market overview.
Chapter 2: Global Oligonucleotide Therapy-based Drug market size in revenue.
Chapter 3: Detailed analysis of Oligonucleotide Therapy-based Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oligonucleotide Therapy-based Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
  • Table Of Content 
    1 Introduction to Research & Analysis Reports
    1.1 Oligonucleotide Therapy-based Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Oligonucleotide Therapy-based Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Oligonucleotide Therapy-based Drug Overall Market Size
    2.1 Global Oligonucleotide Therapy-based Drug Market Size: 2022 VS 2029
    2.2 Global Oligonucleotide Therapy-based Drug Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Oligonucleotide Therapy-based Drug Players in Global Market
    3.2 Top Global Oligonucleotide Therapy-based Drug Companies Ranked by Revenue
    3.3 Global Oligonucleotide Therapy-based Drug Revenue by Companies
    3.4 Top 3 and Top 5 Oligonucleotide Therapy-based Drug Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Oligonucleotide Therapy-based Drug Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Oligonucleotide Therapy-based Drug Players in Global Market
        3.6.1 List of Global Tier 1 Oligonucleotide Therapy-based Drug Companies
        3.6.2 List of Global Tier 2 and Tier 3 Oligonucleotide Therapy-based Drug Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Oligonucleotide Therapy-based Drug Market Size Markets, 2022 & 2029
        4.1.2 Antisense Oligonucleotides (ASO)
        4.1.3 siRNA
        4.1.4 mRNA
    4.2 By Type - Global Oligonucleotide Therapy-based Drug Revenue & Forecasts
        4.2.1 By Type - Global Oligonucleotide Therapy-based Drug Revenue, 2018-2023
        4.2.2 By Type - Global Oligonucleotide Therapy-based Drug Revenue, 2024-2029
        4.2.3 By Type - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Oligonucleotide Therapy-based Drug Market Size, 2022 & 2029
        5.1.2 Neuromuscular Diseases
        5.1.3 hATTR
        5.1.4 COVID-19
        5.1.5 Other
    5.2 By Application - Global Oligonucleotide Therapy-based Drug Revenue & Forecasts
        5.2.1 By Application - Global Oligonucleotide Therapy-based Drug Revenue, 2018-2023
        5.2.2 By Application - Global Oligonucleotide Therapy-based Drug Revenue, 2024-2029
        5.2.3 By Application - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Oligonucleotide Therapy-based Drug Market Size, 2022 & 2029
    6.2 By Region - Global Oligonucleotide Therapy-based Drug Revenue & Forecasts
        6.2.1 By Region - Global Oligonucleotide Therapy-based Drug Revenue, 2018-2023
        6.2.2 By Region - Global Oligonucleotide Therapy-based Drug Revenue, 2024-2029
        6.2.3 By Region - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Oligonucleotide Therapy-based Drug Revenue, 2018-2029
        6.3.2 US Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.3.3 Canada Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.3.4 Mexico Oligonucleotide Therapy-based Drug Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Oligonucleotide Therapy-based Drug Revenue, 2018-2029
        6.4.2 Germany Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.4.3 France Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.4.4 U.K. Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.4.5 Italy Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.4.6 Russia Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.4.7 Nordic Countries Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.4.8 Benelux Oligonucleotide Therapy-based Drug Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Oligonucleotide Therapy-based Drug Revenue, 2018-2029
        6.5.2 China Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.5.3 Japan Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.5.4 South Korea Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.5.5 Southeast Asia Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.5.6 India Oligonucleotide Therapy-based Drug Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Oligonucleotide Therapy-based Drug Revenue, 2018-2029
        6.6.2 Brazil Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.6.3 Argentina Oligonucleotide Therapy-based Drug Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Oligonucleotide Therapy-based Drug Revenue, 2018-2029
        6.7.2 Turkey Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.7.3 Israel Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.7.4 Saudi Arabia Oligonucleotide Therapy-based Drug Market Size, 2018-2029
        6.7.5 UAE Oligonucleotide Therapy-based Drug Market Size, 2018-2029
7 Oligonucleotide Therapy-based Drug Companies Profiles
    7.1 Sarepta Therapeutics
        7.1.1 Sarepta Therapeutics Company Summary
        7.1.2 Sarepta Therapeutics Business Overview
        7.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
        7.1.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.1.5 Sarepta Therapeutics Key News & Latest Developments
    7.2 Ionis Pharmaceuticals
        7.2.1 Ionis Pharmaceuticals Company Summary
        7.2.2 Ionis Pharmaceuticals Business Overview
        7.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Major Product Offerings
        7.2.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.2.5 Ionis Pharmaceuticals Key News & Latest Developments
    7.3 Alnylam
        7.3.1 Alnylam Company Summary
        7.3.2 Alnylam Business Overview
        7.3.3 Alnylam Oligonucleotide Therapy-based Drug Major Product Offerings
        7.3.4 Alnylam Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.3.5 Alnylam Key News & Latest Developments
    7.4 Biogen
        7.4.1 Biogen Company Summary
        7.4.2 Biogen Business Overview
        7.4.3 Biogen Oligonucleotide Therapy-based Drug Major Product Offerings
        7.4.4 Biogen Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.4.5 Biogen Key News & Latest Developments
    7.5 Nippon Shinyaku
        7.5.1 Nippon Shinyaku Company Summary
        7.5.2 Nippon Shinyaku Business Overview
        7.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Major Product Offerings
        7.5.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.5.5 Nippon Shinyaku Key News & Latest Developments
    7.6 Sobi
        7.6.1 Sobi Company Summary
        7.6.2 Sobi Business Overview
        7.6.3 Sobi Oligonucleotide Therapy-based Drug Major Product Offerings
        7.6.4 Sobi Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.6.5 Sobi Key News & Latest Developments
    7.7 Novartis
        7.7.1 Novartis Company Summary
        7.7.2 Novartis Business Overview
        7.7.3 Novartis Oligonucleotide Therapy-based Drug Major Product Offerings
        7.7.4 Novartis Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.7.5 Novartis Key News & Latest Developments
    7.8 BioNTech
        7.8.1 BioNTech Company Summary
        7.8.2 BioNTech Business Overview
        7.8.3 BioNTech Oligonucleotide Therapy-based Drug Major Product Offerings
        7.8.4 BioNTech Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.8.5 BioNTech Key News & Latest Developments
    7.9 Pfizer
        7.9.1 Pfizer Company Summary
        7.9.2 Pfizer Business Overview
        7.9.3 Pfizer Oligonucleotide Therapy-based Drug Major Product Offerings
        7.9.4 Pfizer Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.9.5 Pfizer Key News & Latest Developments
    7.10 Moderna Therapeutics
        7.10.1 Moderna Therapeutics Company Summary
        7.10.2 Moderna Therapeutics Business Overview
        7.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
        7.10.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.10.5 Moderna Therapeutics Key News & Latest Developments
    7.11 Jazz Pharmaceuticals
        7.11.1 Jazz Pharmaceuticals Company Summary
        7.11.2 Jazz Pharmaceuticals Business Overview
        7.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Major Product Offerings
        7.11.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.11.5 Jazz Pharmaceuticals Key News & Latest Developments
    7.12 CureVac
        7.12.1 CureVac Company Summary
        7.12.2 CureVac Business Overview
        7.12.3 CureVac Oligonucleotide Therapy-based Drug Major Product Offerings
        7.12.4 CureVac Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.12.5 CureVac Key News & Latest Developments
    7.13 Regulus Therapeutics
        7.13.1 Regulus Therapeutics Company Summary
        7.13.2 Regulus Therapeutics Business Overview
        7.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
        7.13.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.13.5 Regulus Therapeutics Key News & Latest Developments
    7.14 ProQR
        7.14.1 ProQR Company Summary
        7.14.2 ProQR Business Overview
        7.14.3 ProQR Oligonucleotide Therapy-based Drug Major Product Offerings
        7.14.4 ProQR Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.14.5 ProQR Key News & Latest Developments
    7.15 Secarna
        7.15.1 Secarna Company Summary
        7.15.2 Secarna Business Overview
        7.15.3 Secarna Oligonucleotide Therapy-based Drug Major Product Offerings
        7.15.4 Secarna Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.15.5 Secarna Key News & Latest Developments
    7.16 MiNA Therapeutics
        7.16.1 MiNA Therapeutics Company Summary
        7.16.2 MiNA Therapeutics Business Overview
        7.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
        7.16.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.16.5 MiNA Therapeutics Key News & Latest Developments
    7.17 Sylentis
        7.17.1 Sylentis Company Summary
        7.17.2 Sylentis Business Overview
        7.17.3 Sylentis Oligonucleotide Therapy-based Drug Major Product Offerings
        7.17.4 Sylentis Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.17.5 Sylentis Key News & Latest Developments
    7.18 Arrowhead
        7.18.1 Arrowhead Company Summary
        7.18.2 Arrowhead Business Overview
        7.18.3 Arrowhead Oligonucleotide Therapy-based Drug Major Product Offerings
        7.18.4 Arrowhead Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.18.5 Arrowhead Key News & Latest Developments
    7.19 Silence Therapeutics
        7.19.1 Silence Therapeutics Company Summary
        7.19.2 Silence Therapeutics Business Overview
        7.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
        7.19.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.19.5 Silence Therapeutics Key News & Latest Developments
    7.20 Dicerna
        7.20.1 Dicerna Company Summary
        7.20.2 Dicerna Business Overview
        7.20.3 Dicerna Oligonucleotide Therapy-based Drug Major Product Offerings
        7.20.4 Dicerna Oligonucleotide Therapy-based Drug Revenue in Global Market (2018-2023)
        7.20.5 Dicerna Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer
  • Inquiry Before Buying

    Inquiry Before Buying

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday
  • Request Sample

    Request For Sample

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday


Our Trusted Clients
cooper.fr
koronos
waldenmedical
unioncomm.co.kr
technopathclinicaldiagnostics
toho-titanium.co.jp
straubmedical
sew-eurodrive.de
medurifarms
naperol
nvent
network.ae
petronas
saeedghodran
polyworldsys
seedplanning.co.jp
kraton
ipms.fraunhofer.de
infanttech
httpswww.castel-freres
hintoninfo
hexcel
freightways.co.nz
excelitas
Acco
aspet
brand
bmc
elevate
europ-assistance


GET IN TOUCH
Phone: +1 (415) 315-9432
Phone: +91 86698 89536
Email: inquiry@wiredrelease.com
SHORT NAVIGATION
connect with us